In this issue:
Namilumab in RA
Safety and efficacy of tofacitinib for up to 9.5 years in RA
Withdrawal of infliximab in AS
Early treatment of PsA with TNFi
Stopping TCZ in GCA
Mortality in RA
Conflict of interest and RA trials
Ixekizumab for radiographic axSpA
Pain susceptibility phenotypes and knee OA
Please login below to download this issue (PDF)